In clinical practice, pathological examination including estimation of tumor-infiltrating lymphocytes (TILs) or immunohistochemistry for AR, gross cystic disease fluid protein 15 (GCDFP-15), EGFR, CK5/6, E-cadherin, or PD-L1 is expected as a substitute for molecular analysis [12,50,51,52,53,54,55]. This evidence concerns the gene AR and neoplasm.